Simulations Plus (SLP) Scheduled to Post Quarterly Earnings on Tuesday

Simulations Plus (NASDAQ:SLP) will be posting its quarterly earnings results after the market closes on Tuesday, July 2nd. Analysts expect Simulations Plus to post earnings of $0.17 per share for the quarter. Simulations Plus has set its FY24 guidance at $0.66-0.68 EPS and its FY 2024 guidance at 0.660-0.680 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, April 3rd. The technology company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $18.31 million for the quarter, compared to analysts’ expectations of $17.31 million. Simulations Plus had a net margin of 16.22% and a return on equity of 7.95%. The business’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 earnings per share. On average, analysts expect Simulations Plus to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Simulations Plus Stock Up 1.5 %

Shares of Simulations Plus stock opened at $48.62 on Friday. The company has a market cap of $971.67 million, a price-to-earnings ratio of 91.74 and a beta of 0.75. The company’s 50 day moving average is $47.77 and its 200 day moving average is $44.09. Simulations Plus has a twelve month low of $32.69 and a twelve month high of $52.69.

Simulations Plus Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 6th. Investors of record on Monday, April 29th were given a dividend of $0.06 per share. The ex-dividend date of this dividend was Friday, April 26th. This represents a $0.24 dividend on an annualized basis and a yield of 0.49%. Simulations Plus’s dividend payout ratio (DPR) is 45.28%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SLP. Oppenheimer increased their price objective on shares of Simulations Plus from $55.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, June 13th. William Blair started coverage on shares of Simulations Plus in a research report on Friday. They set an “outperform” rating on the stock. Finally, Craig Hallum increased their price target on shares of Simulations Plus from $51.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th.

Insiders Place Their Bets

In other Simulations Plus news, Director Daniel L. Weiner sold 3,250 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $48.31, for a total value of $157,007.50. Following the transaction, the director now directly owns 8,759 shares in the company, valued at $423,147.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Daniel L. Weiner sold 3,250 shares of the stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $48.31, for a total value of $157,007.50. Following the completion of the sale, the director now directly owns 8,759 shares of the company’s stock, valued at $423,147.29. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total transaction of $919,000.00. Following the completion of the sale, the director now directly owns 3,580,857 shares of the company’s stock, valued at $164,540,379.15. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,750 shares of company stock worth $1,899,808. Company insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.